These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8728055)

  • 41. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.
    Pialoux G; Excler JL; Rivière Y; Gonzalez-Canali G; Feuillie V; Coulaud P; Gluckman JC; Matthews TJ; Meignier B; Kieny MP
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):373-81. PubMed ID: 7598771
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with gp160 in HIV.
    Stanberry LR; Bernstein DI; Myers MG
    N Engl J Med; 1992 Jan; 326(5):347-8. PubMed ID: 1728748
    [No Abstract]   [Full Text] [Related]  

  • 43. Designing peptide vaccines to broaden recognition and enhance potency.
    Berzofsky JA
    Ann N Y Acad Sci; 1995 May; 754():161-8. PubMed ID: 7625650
    [No Abstract]   [Full Text] [Related]  

  • 44. Complement activation by gp160 glycoprotein of HIV-1.
    Thieblemont N; Haeffner-Cavaillon N; Weiss L; Maillet F; Kazatchkine MD
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):229-33. PubMed ID: 8471312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The quest for an antibody-based HIV vaccine.
    Haynes BF; Mascola JR
    Immunol Rev; 2017 Jan; 275(1):5-10. PubMed ID: 28133795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation.
    Wang B; Boyer J; Srikantan V; Ugen K; Gilbert L; Phan C; Dang K; Merva M; Agadjanyan MG; Newman M
    Virology; 1995 Aug; 211(1):102-12. PubMed ID: 7645204
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical trials of AIDS vaccines in seronegative volunteers: vectors and combinations.
    Graham BS
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1327-8. PubMed ID: 1466951
    [No Abstract]   [Full Text] [Related]  

  • 48. Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.
    Pincus SH; Messer KG; Schwartz DH; Lewis GK; Graham BS; Blattner WA; Fisher G
    J Clin Invest; 1993 May; 91(5):1987-96. PubMed ID: 7683694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine.
    Wu JY; Gardner BH; Murphy CI; Seals JR; Kensil CR; Recchia J; Beltz GA; Newman GW; Newman MJ
    J Immunol; 1992 Mar; 148(5):1519-25. PubMed ID: 1538134
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Bona C; Nixon A; Kennedy R; Zaghouani H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1377. PubMed ID: 1466959
    [No Abstract]   [Full Text] [Related]  

  • 52. Diversity considerations in HIV-1 vaccine selection.
    Gaschen B; Taylor J; Yusim K; Foley B; Gao F; Lang D; Novitsky V; Haynes B; Hahn BH; Bhattacharya T; Korber B
    Science; 2002 Jun; 296(5577):2354-60. PubMed ID: 12089434
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clonal analysis of T-cell responses to the HIV-1 envelope proteins in AIDS vaccine recipients.
    Siliciano RF; Bollinger RC; Callahan KM; Hammond SA; Liu AY; Miskovsky EP; Rowell JF; Stanhope PE
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1349-52. PubMed ID: 1361352
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Production in rabbits of high levels of anti-HIV-1 gp160 antibodies.
    Relyveld E; Bizzini B
    Cell Mol Biol (Noisy-le-grand); 1995 May; 41(3):389-93. PubMed ID: 7580832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
    Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
    Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
    [No Abstract]   [Full Text] [Related]  

  • 57. Studies of high doses of a human immunodeficiency virus type 1 recombinant glycoprotein 160 candidate vaccine in HIV type 1-seronegative humans. The AIDS Vaccine Clinical Trials Network.
    Keefer MC; Graham BS; Belshe RB; Schwartz D; Corey L; Bolognesi DP; Stablein DM; Montefiori DC; McElrath MJ; Clements ML
    AIDS Res Hum Retroviruses; 1994 Dec; 10(12):1713-23. PubMed ID: 7888231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice.
    Shirai A; Klinman DM
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):979-83. PubMed ID: 8280480
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase I/II studies of the toxicity and immunogenicity of recombinant gp160 and p24 vaccines in HIV-infected individuals.
    Zunich KM; Lane HC; Davey RT; Falloon J; Polis M; Kovacs JA; Masur H
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1335. PubMed ID: 1466952
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.